Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch

Jun 28 2012

• By Cathy Dombrowski

Related Content

Recent Round Of Obesity Reviews Suggests CV Safety Standards Have Come Into Focus

May 21 2012

Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study

Feb 22 2012

Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden

Feb 27 2012

With SPA Finalized, Orexigen To Begin CV Outcomes Study For <em>Contrave</em> In Second Quarter

Feb 06 2012

Panel Continues To Push For Obesity CV Guidance As It Backs <i>Contrave</i> Approval

Dec 13 2010

Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date

Jul 01 2010

Related Companies

Arena Pharmaceuticals, Inc.

Vivus, Inc.

Eisai Co., Ltd.

Orexigen Therapeutics, Inc.

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window